England Sees Past Price Tag To Back GSK Bubble Baby Gene Therapy
The cost of Strimvelis for treating severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is €594,000 but NICE has confirmed that it thinks the benefits of GSK's gene therapy, administered at a hospital in Milan, represents a fair price.
You may also be interested in...
Having recently got hold of GlaxoSmithKline's gene therapy assets, Orchard has completed another whopping financing which has got observers thinking that an IPO could soon be in the offing.
NICE, the HTA body for England and Wales, has for the first time recommended a treatment – GSK’s gene therapy, Strimvelis – that is currently only available in another country. Also for the first time, NICE used a new system for determining the cost-effectiveness of highly specialized technologies such as this.
Spark's gene therapy for patients with an inherited form of blindness will be available in the US late in the first quarter, but on the big question – whether it will cost $1m for the one-time treatment – Spark would not say.